Lava Therapeutics (Netherlands)

Recent papers from Lava Therapeutics (Netherlands)

1. Lenalidomide boosts CD1d-Vδ2 bispecific antibody-engaged Vγ9Vδ2-T cell effector functions via CD28, Notch signaling and IL-2 releaseJournal for ImmunoTherapy of Cancer · 2026
2. A trophoblast glycoprotein specific 5T4-Vδ2 bispecific T cell engager recruits Vγ9Vδ2-T cells for tumor-selective cytotoxicity across solid malignanciesClinical Immunology · 2026
3. PD-L1 directed bispecific Vδ2-T cell engager combines lysis of PD-L1 expressing tumor cells with PD-1 immune checkpoint inhibition and modulation of the tumor immune microenvironmentJournal for ImmunoTherapy of Cancer · 2025
4. Leveraging Vγ9Vδ2 T cells against prostate cancer through a VHH-based PSMA-Vδ2 bispecific T cell engageriScience · 2024
5. Vδ2 T-cell engagers bivalent for Vδ2-TCR binding provide anti-tumor immunity and support robust Vγ9Vδ2 T-cell expansionFrontiers in Oncology · 2024
6. Phase I/II trial of LAVA-1207, a novel bispecific gamma-delta T-cell engager alone, or with low dose IL-2 or pembrolizumab, in metastatic castration resistant prostate cancer (mCRPC).Journal of Clinical Oncology · 2024
7. Vaccination with DC-SIGN-Targeting αGC Liposomes Leads to Tumor Control, Irrespective of Suboptimally Activated T-CellsPharmaceutics · 2024
8. Integrative Kinase Activity Profiling and Phosphoproteomics of rd10 Mouse Retina during cGMP-Dependent Retinal DegenerationInternational Journal of Molecular Sciences · 2024
9. Allogeneic NK cells induce the in vitro activation of monocyte-derived and conventional type-2 dendritic cells and trigger an inflammatory response under cancer-associated conditionsClinical & Experimental Immunology · 2024
10. Human anti-C1q autoantibodies bind specifically to solid-phase C1q and enhance phagocytosis but not complement activationProceedings of the National Academy of Sciences · 2023
11. Enhanced CD1d phosphatidylserine presentation using a single-domain antibody promotes immunomodulatory CD1d-TIM-3 interactionsJournal for ImmunoTherapy of Cancer · 2023
12. Allogeneic NK cells induce monocyte-to-dendritic cell conversion, control tumor growth, and trigger a pro-inflammatory shift in patient-derived cultures of primary and metastatic colorectal cancerJournal for ImmunoTherapy of Cancer · 2023
13. A Bispecific γδ T-cell Engager Targeting EGFR Activates a Potent Vγ9Vδ2 T cell–Mediated Immune Response against EGFR-Expressing TumorsCancer Immunology Research · 2023
14. A bispecific T cell engager recruits both type 1 NKT and Vγ9Vδ2-T cells for the treatment of CD1d-expressing hematological malignanciesCell Reports Medicine · 2023
15. Antibodies as drugs—a Keystone Symposia reportAnnals of the New York Academy of Sciences · 2022
16. Systemic Therapy for Patients with HER2-Positive Breast Cancer and Brain Metastases: A Systematic Review and Meta-AnalysisCancers · 2022
17. Systematic study of tissue factor expression in solid tumorsCancer Reports · 2022
18. Directing HIV-1 for degradation by non-target cells, using bi-specific single-chain llama antibodiesScientific Reports · 2022
19. Avidity in antibody effector functions and biotherapeutic drug designNature Reviews Drug Discovery · 2022
20. Gamma Delta T-Cell Based Cancer Immunotherapy: Past-Present-FutureFrontiers in Immunology · 2022